GLP-1s and Atrial Fibrillation: Can Weight Loss Help AFib? | SourceGLP-1
Dec 25, 2025
Weight loss reduces AFib burden significantly. How GLP-1 medications may help atrial fibrillation through weight loss and beyond.
Latest Blog Posts
GLP-1s and Chronic Pain: Can Weight Loss Reduce Pain? | SourceGLP-1
Dec 25, 2025
How GLP-1 weight loss medications may improve chronic pain conditions. The obesity-pain connection, anti-inflammatory effects, and what patients report.
GLP-1s for Dementia: Why EVOKE Failed and What's Next | SourceGLP-1
Dec 25, 2025
The EVOKE trial of semaglutide for Alzheimer's didn't show benefit. But observational data suggests protection. Here's what we know about GLP-1s and brain health.
GLP-1s and Gout: Can Weight Loss Lower Uric Acid? | SourceGLP-1
Dec 25, 2025
GLP-1 medications may help gout by lowering uric acid levels. The obesity-gout connection, research on semaglutide and uric acid, and what patients report.
Drinking on GLP-1s: Alcohol Interactions, Risks, and What to Know | SourceGLP-1
Dec 24, 2025
Can you drink alcohol on Ozempic or Zepbound? The science on GLP-1 alcohol interactions: hypoglycemia risk, slower metabolism, reduced cravings, and liver protection research.
GLP-1 Injection Technique: Sites, Rotation, and Pro Tips | SourceGLP-1
Dec 24, 2025
Complete guide to injecting semaglutide and tirzepatide: best injection sites, rotation patterns, preparation steps, and techniques for reducing pain and anxiety.
Managing GLP-1 Nausea: Causes, Timeline, and What Actually Works | SourceGLP-1
Dec 24, 2025
Complete guide to managing nausea on semaglutide and tirzepatide: why it happens, how long it lasts, foods that help, medications like Zofran, and when to call your doctor.
Switching GLP-1 Medications: When to Change and How to Do It Right | SourceGLP-1
Dec 24, 2025
Complete guide to switching from semaglutide to tirzepatide or between GLP-1 providers: when to switch, dose conversion, avoiding gaps, and what to expect.
Compounded GLP-1 Guide: 503A vs 503B, Quality Markers & Red Flags | SourceGLP-1
Dec 23, 2025
How to evaluate compounding pharmacies for semaglutide and tirzepatide. 503A vs 503B explained, PCAB accreditation, COA verification, FDA warning signs, and 15 questions to ask before buying.
GLP-1 Drug Interactions: Insulin, Birth Control, Thyroid Meds & More | SourceGLP-1
Dec 23, 2025
Complete guide to GLP-1 medication interactions with insulin, sulfonylureas, birth control, levothyroxine, warfarin, and alcohol. Based on FDA labels and 2025 ADA guidelines.
GLP-1 Insurance Coverage 2025: Prior Authorization, Appeals & Savings Programs | SourceGLP-1
Dec 23, 2025
Navigate GLP-1 insurance in 2025: Medicare/Medicaid coverage by state, commercial plan restrictions, prior auth strategies, appeal tactics, and manufacturer savings programs up to $350/month.
When to Stop GLP-1 Medications: Surgery, Pregnancy, Side Effects & Plateaus | SourceGLP-1
Dec 23, 2025
Complete guide on when to pause or stop semaglutide and tirzepatide. Covers pre-surgery protocols, pregnancy planning, adverse events, weight plateaus, and what happens when you stop.
GLP-1 Drugs and Alzheimer's: Why the Largest Trials Failed Despite Promising Signs | SourceGLP-1
Dec 23, 2025
The EVOKE trials testing semaglutide for Alzheimer's disease failed their primary endpoints in November 2025. Here's what the data actually showed and what it means.
STEP-HFpEF: Semaglutide Transforms Heart Failure with Preserved Ejection Fraction | SourceGLP-1
Dec 23, 2025
Semaglutide dramatically improved symptoms, exercise capacity, and quality of life in HFpEF patients. NEJM data shows this may be the breakthrough treatment for the most common form of heart failure.
GLP-1 Drugs and Inflammation: Emerging Evidence for Autoimmune Conditions | SourceGLP-1
Dec 23, 2025
New data suggests GLP-1 drugs may reduce inflammation markers and autoimmune disease risk. Here's what the research shows for rheumatoid arthritis, psoriasis, and IBD.
FLOW Trial: Semaglutide Reduces Kidney Disease Progression by 24% | SourceGLP-1
Dec 23, 2025
The landmark FLOW trial showed semaglutide reduced major kidney events and death in diabetic kidney disease. Published in NEJM, stopped early for efficacy.
GLP-1 Drugs Show Promise for Parkinson's Disease: The Phase 2 Data | SourceGLP-1
Dec 23, 2025
Lixisenatide stopped motor symptom progression in early Parkinson's patients. Here's what the NEJM trial found and what's coming next.
SURMOUNT-OSA: Tirzepatide Cuts Sleep Apnea Severity by 50-60% | SourceGLP-1
Dec 23, 2025
Tirzepatide dramatically reduced sleep apnea severity in obese patients, potentially offering an alternative to CPAP. NEJM results show up to 63% AHI reduction.
GLP-1s and Anhedonia: The Pleasure-Killing Concern | SourceGLP-1
Dec 23, 2025
If GLP-1s dampen the reward system, could they reduce pleasure from everything—not just food and drugs? What we know about anhedonia risk.
Brain Receptor Map: Where GLP-1s Work in the Reward System | SourceGLP-1
Dec 23, 2025
GLP-1 receptors in the VTA, nucleus accumbens, and prefrontal cortex may explain why these drugs affect cravings. A visual guide to the neuroscience.
Why First-Gen GLP-1s Failed for Addiction (And Semaglutide Might Succeed) | SourceGLP-1
Dec 23, 2025
Exenatide and liraglutide trials for alcohol and cocaine showed mixed results. Why researchers think semaglutide's different pharmacology could change outcomes.
GLP-1s for MASH/Fatty Liver: Semaglutide's New FDA Approval | SourceGLP-1
Dec 23, 2025
Semaglutide received FDA approval for MASH in August 2025—the second drug ever approved for fatty liver disease. Phase 3 trial data, tirzepatide pipeline, and what it means.
The "Prozac Moment" for Addiction: Why Researchers Are Excited About GLP-1s | SourceGLP-1
Dec 23, 2025
Why addiction researchers are calling GLP-1s the most exciting development in 15 years. Expert quotes, trial pipeline, and what breakthrough potential really means.
GLP-1s for Binge Eating Disorder: Beyond Weight Loss | SourceGLP-1
Dec 23, 2025
Semaglutide shows promise for binge eating disorder in early studies. We analyze the research, compare to FDA-approved treatments, and explain what's different about BED.
Semaglutide and Cannabis Use Disorder: The Molecular Psychiatry Study | SourceGLP-1
Dec 23, 2025
A study of 680,000+ patients found semaglutide users were 44-60% less likely to develop cannabis use disorder. We break down the Wang et al. 2024 findings.
GLP-1s for Cocaine Addiction: The Emerging Research | SourceGLP-1
Dec 23, 2025
Semaglutide reduced cocaine self-administration by 26% in rats and cocaine-seeking by 62%. We analyze the University of Gothenburg study and $2.7M UTHealth trial.
GLP-1 Taste Changes: Why Food Tastes Different on Ozempic | SourceGLP-1
Dec 23, 2025
Why does food taste different on semaglutide? New research shows GLP-1 drugs actually change taste bud gene expression and brain response to sweetness.
The Ozempic Plateau: Why Weight Loss Stalls and What the Data Says | SourceGLP-1
Dec 23, 2025
Weight loss stopped on Ozempic? Research shows plateaus typically occur around 60-68 weeks. Here's why it happens and what to do about it.
Zepbound FDA Approval for Sleep Apnea: The Complete SURMOUNT-OSA Data | SourceGLP-1
Dec 23, 2025
On December 20, 2024, the FDA approved Zepbound as the first-ever medication for obstructive sleep apnea. Here's what the SURMOUNT-OSA trial actually showed.
Compounded vs Brand-Name Semaglutide: Safety Data Compared | SourceGLP-1
Dec 23, 2025
FDA testing found compounded semaglutide potency ranging 42-170% of labeled dose. FAERS reports 442 adverse events. Here's the complete safety comparison.
"Ozempic Dreams" — Why GLP-1 Users Report Vivid, Bizarre Dreams | SourceGLP-1
Dec 23, 2025
Thousands report strange, vivid dreams on semaglutide. Shopping with Clint Eastwood, robbing museums with celebrities. Here's the neuroscience and what Novo Nordisk says.
Can GLP-1s Cause Depression? Examining the Evidence | SourceGLP-1
Dec 23, 2025
FDA and EMA investigations, FAERS data, WHO database analysis, and controlled studies on semaglutide and mental health. The complete picture with sources.
GLP-1s & Opioid Addiction: Penn State's Breakthrough Research | SourceGLP-1
Dec 23, 2025
Can semaglutide reduce opioid cravings? Penn State researchers found a 40% reduction in cravings in early trials. Here's the data from NIH-funded studies.
GLP-1 Pricing Exposed: From API Cost to Your Pharmacy Bill | SourceGLP-1
Dec 23, 2025
The raw ingredient for a month of Ozempic costs under $50. So why does a prescription cost $1,000+? Breaking down the GLP-1 pricing chain with sources.
Novo Nordisk's 111+ Trademark Lawsuits Against Compounders: Full Tracker | SourceGLP-1
Dec 23, 2025
Novo Nordisk has filed 111+ lawsuits against compounding pharmacies and telehealth companies. Track every case, outcome, and what it means for compounded semaglutide.
Does Ozempic Kill Your Alcohol Cravings? (Source: Yes, Here's Why) | SourceGLP-1
Dec 23, 2025
Randomized trial data confirms semaglutide reduces alcohol consumption. The neuroscience of why GLP-1 drugs decrease drinking—verified with sources.
Can You Get Ozempic Without a Prescription? (Source: No) | SourceGLP-1
Dec 23, 2025
Ozempic requires a valid prescription in the US. Here's why, what the legal requirements are, and how to access it legitimately.
Sulfur Burps Explained: The GI Science Behind GLP-1 Side Effects | SourceGLP-1
Dec 23, 2025
Why do Ozempic and Wegovy cause rotten egg burps? The science of delayed gastric emptying, hydrogen sulfide, and evidence-based relief strategies.
Compounded GLP-1 Potency: What Testing Actually Reveals | SourceGLP-1
Dec 23, 2025
FDA testing data, Novo Nordisk analyses, and independent assays reveal wide potency variation in compounded semaglutide—from 0% to over 120% of labeled strength.
Compounded GLP-1 Potency Variation: What Lab Testing Actually Shows | SourceGLP-1
Dec 23, 2025
Independent lab testing of compounded semaglutide found products ranging from 42% to 170% of labeled potency. Here's what the data reveals about quality variation.
GLP-1s & Fertility: The "Ozempic Baby" Research | SourceGLP-1
Dec 23, 2025
What does science actually say about 'Ozempic babies'? Complete analysis of GLP-1 fertility research in PCOS, weight loss effects, birth control interactions, and pregnancy safety data.
GLP-1 Muscle Loss: How Much Lean Mass Do Users Actually Lose? | SourceGLP-1
Dec 23, 2025
Comprehensive analysis of body composition data from STEP, SURMOUNT, and SURPASS trials. What DXA and MRI studies reveal about semaglutide and tirzepatide effects on lean mass.
GLP-1s & Testosterone: What the Studies Actually Show | SourceGLP-1
Dec 23, 2025
Research shows GLP-1 medications can increase testosterone levels in men with obesity by 18% on average. Here's the complete data on hormonal effects.
Next-Gen GLP-1s: Retatrutide, Amycretin & Orforglipron Trial Data | SourceGLP-1
Dec 23, 2025
Retatrutide delivers 28.7% weight loss in Phase 3. Amycretin hits 22%. Orforglipron offers needle-free daily pill. Complete trial data on what's coming next.
Oral vs Injectable Semaglutide: The Bioavailability Data | SourceGLP-1
Dec 23, 2025
Oral semaglutide (Rybelsus) has 0.4-1% bioavailability vs. 89% for injectable. Here's the complete pharmacokinetic comparison and what it means for efficacy.
"Ozempic Face" — Dermatologists Explain the Aging Effect | SourceGLP-1
Dec 23, 2025
Rapid GLP-1 weight loss can cause facial volume loss, sagging skin, and premature aging. Here's what dermatologists and plastic surgeons say—with data.
The SELECT Trial: How GLP-1s Became Heart Medications | SourceGLP-1
Dec 23, 2025
Complete analysis of the SELECT trial that proved semaglutide reduces heart attacks, strokes, and cardiovascular death in people without diabetes. 17,604 patients, 20% risk reduction.
Weight Regain After Stopping GLP-1s: The Complete Clinical Trial Data | SourceGLP-1
Dec 23, 2025
What happens when you stop semaglutide or tirzepatide? We analyze the STEP 1 extension, SURMOUNT-4, and real-world data on weight regain and prevention strategies.
503A vs 503B: The Complete Framework for GLP-1 Compounding | SourceGLP-1
Dec 22, 2025
Understand the FDA's 503A and 503B compounding designations. Learn how they affect your semaglutide and tirzepatide prescriptions, quality standards, and what certifications to look for.
Celebrities Who've Confirmed GLP-1 Use (Updated List) | SourceGLP-1
Dec 22, 2025
Which celebrities have actually admitted to using Ozempic, Wegovy, or Mounjaro? We tracked down the direct quotes — no speculation, just confirmed statements.
EVOKE Trial Results: Semaglutide Fails Alzheimer's Test — But Prevention Story Remains | SourceGLP-1
Dec 22, 2025
Complete analysis of the EVOKE and EVOKE+ Phase 3 trials. Semaglutide didn't slow Alzheimer's progression, but biomarker data and observational studies suggest prevention potential remains.
All 50+ FDA Warning Letters (Sept 2025): Full Text & Analysis | SourceGLP-1
Dec 22, 2025
The FDA sent 50+ warning letters to GLP-1 compounders in September 2025. We've compiled every letter with analysis of what triggered enforcement.
Food Noise Explained: The Brain Science Behind GLP-1 Medications | SourceGLP-1
Dec 22, 2025
fMRI brain imaging reveals how GLP-1 medications reduce food cravings and intrusive food thoughts. Primary research from Nature Medicine and clinical trials.
GLP-1s for Alcoholism: What the JAMA Study Actually Found | SourceGLP-1
Dec 22, 2025
The first randomized controlled trial of semaglutide for alcohol use disorder is here. We break down exactly what the February 2025 JAMA Psychiatry study found.
GLP-1 Compounding Legal Status: What Happens Now That the Shortage Is Over | SourceGLP-1
Dec 22, 2025
The FDA declared semaglutide and tirzepatide shortages resolved. Here's what's still legal for compounding, the clinical difference exception, pending lawsuits, and what it means for patients.
GLP-1 Timeline: Every FDA Approval from 2005 to Today | SourceGLP-1
Dec 22, 2025
Complete chronological history of GLP-1 medication FDA approvals. From Byetta (2005) to today's expanded indications for cardiovascular protection, sleep apnea, and kidney disease.
Hair Loss on GLP-1s: Every Study Analyzed | SourceGLP-1
Dec 22, 2025
Is GLP-1 hair loss real? We reviewed every FAERS analysis, cohort study, and dermatology paper. Here's what the data actually shows.
"Ozempic Penis" — What Urologists Actually Say | SourceGLP-1
Dec 22, 2025
Men on semaglutide report their penis 'got bigger.' We talked to Yale urologists and reviewed the research. Here's what the evidence actually shows.
Your First Week on GLP-1: What to Expect | SourceGLP-1
Dec 22, 2025
Day-by-day guide to your first week on GLP-1 medication. What's normal, what's not, and how to set yourself up for success.
GLP-1 Constipation: Solutions That Actually Work | SourceGLP-1
Dec 22, 2025
Practical fixes for GLP-1-related constipation. Why it happens and what to do about it.
How Much Does GLP-1 Actually Cost? (2025 Price Breakdown) | SourceGLP-1
Dec 22, 2025
Real GLP-1 prices from real providers. What you'll actually pay for semaglutide and tirzepatide in 2025, including brand-name and compounded options.
What Disqualifies You From GLP-1? (And What Doesn't) | SourceGLP-1
Dec 22, 2025
GLP-1 eligibility explained. BMI requirements, medical conditions, and common myths busted. Find out if you qualify.
GLP-1 in 5 Minutes: Everything You Need to Know | SourceGLP-1
Dec 22, 2025
The quick primer on GLP-1 medications. What they are, how they work, and whether they're right for you. No medical jargon, just facts.
GLP-1 Nausea: 8 Ways to Beat It | SourceGLP-1
Dec 22, 2025
Practical solutions for GLP-1 nausea. What causes it, when it improves, and 8 strategies that actually work.
GLP-1 Provider Red Flags: What to Watch For | SourceGLP-1
Dec 22, 2025
How to spot sketchy GLP-1 telehealth providers. Red flags, warning signs, and what legitimate providers do differently.
The GLP-1 Starter Checklist: Everything to Have Ready | SourceGLP-1
Dec 22, 2025
Your complete prep list before starting GLP-1 treatment. Documents, supplies, questions to ask, and how to set yourself up for success.
How to Get GLP-1 Through Telehealth (Step-by-Step) | SourceGLP-1
Dec 22, 2025
The exact process from quiz to delivery. How telehealth GLP-1 prescriptions work, what to expect, and how long it takes.
Injectable vs Oral vs Sublingual GLP-1: Which Form is Right for You? | SourceGLP-1
Dec 22, 2025
GLP-1 delivery methods compared. Needles vs pills vs drops. Pros, cons, and which format fits your lifestyle.
Semaglutide 101: The Complete Beginner's Guide | SourceGLP-1
Dec 22, 2025
Everything you need to know about semaglutide. How it works, what to expect, dosing, side effects, and results from clinical trials.
Semaglutide vs Tirzepatide: Which One Should You Pick? | SourceGLP-1
Dec 22, 2025
Head-to-head comparison of semaglutide and tirzepatide. Efficacy, side effects, cost, and who each medication works best for.
Tirzepatide 101: The Complete Beginner's Guide | SourceGLP-1
Dec 22, 2025
Everything you need to know about tirzepatide (Mounjaro/Zepbound). How it works, dosing, what to expect, and why it's different from semaglutide.